Early TTR Rise on Tafamidis Tied to Lower Death Risk in ATTR-CM Trial Analysis

A post hoc analysis of the pivotal phase 3 ATTR-ACT trial has found that patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who showed an early rise in transthyretin (TTR) concentration after starting tafamidis experienced markedly lower all-cause mortality over the following 30 months. The study, published in Cardiology and Therapy, reports that treatment with tafamidis 80 mg raised mean TTR concentration by 36.3% within the first month of therapy, an increase that persisted through month 30, while patients receiving placebo showed essentially no change.

ATTR-CM is a progressive and fatal disease driven by the dissociation, misfolding and aggregation of TTR protein, which deposits as amyloid fibrils in the heart muscle. The accumulating fibrils thicken ventricular walls, impair diastolic function, trigger arrhythmias and ultimately cause heart failure. Without treatment, median survival ranges from 3.6 to 4.8 years in wild-type disease and 2.6 to 5.8 years in hereditary variant disease, depending on the specific TTR variant. Lower baseline serum TTR concentrations before treatment have previously been linked to poorer survival and worsening cardiac function.

Tafamidis works as a kinetic stabilizer, binding to the thyroxine-binding sites of the native TTR tetramer and slowing its dissociation into monomers that would otherwise misfold and aggregate. In the original ATTR-ACT trial, tafamidis demonstrated a statistically significant reduction in mortality at 30 months compared with placebo. Nearly 90% of patients receiving the 80 mg dose achieved TTR stabilization in that trial, and real-world studies have likewise reported increases in TTR concentration after treatment initiation.

The new analysis focused on 175 patients treated with tafamidis 80 mg and 175 treated with placebo who survived to month 1 and had TTR concentration data available. Patients randomized to tafamidis showed a mean increase in TTR of 7.3 mg/dL by month 1, whereas the placebo group recorded a mean change of just −0.02 mg/dL. The tafamidis-associated increase was sustained through month 30 among patients with available data.

The mortality link emerged most clearly in univariate analyses. In a logistic regression model adjusted for baseline TTR concentration, every 1 mg/dL increase in TTR at month 1 was associated with an 11.3% reduction in the odds of death by month 30 among tafamidis-treated patients (odds ratio 0.887; 95% confidence interval 0.803–0.981; p = 0.0193), and every 5 mg/dL increase corresponded to a 45.0% reduction in odds. No significant association appeared in the placebo group, where TTR levels barely moved. In a univariate Cox model for time to death, each 1 mg/dL increase at month 1 was associated with a 9.3% reduction in the hazard of death (hazard ratio 0.907; 95% CI 0.837–0.983; p = 0.0174), and each 5 mg/dL increase with a 38.5% reduction.

Subgroup analyses suggested the association was stronger in several patient categories, including those in NYHA class I/II, patients younger than 80, those with eGFR of at least 45 mL/min/1.73 m², wild-type TTR genotype, baseline TTR below 20 mg/dL, and patients using diuretics. However, when the researchers built a multivariable Cox model with backward selection, retaining baseline TTR concentration and National Amyloidosis Centre stage as covariates, the association between early TTR change and mortality in the tafamidis 80 mg group narrowly missed statistical significance: each 1 mg/dL increase was associated with an 8.7% hazard reduction (hazard ratio 0.913; 95% CI 0.832–1.001; p = 0.0538).

The authors attribute this borderline result to the modest sample size, which may have reduced the statistical power of the adjusted analysis. In a sensitivity analysis that expanded the cohort roughly 1.5-fold by including patients who received the 20 mg tafamidis dose, increasing the sample from 166 to 252, the association became clearly significant: each 1 mg/dL increase in TTR concentration was associated with an 11.2% decrease in the hazard of death (hazard ratio 0.888; 95% CI 0.825–0.955; p = 0.0014). Baseline TTR concentration and NAC stage remained the selected covariates in that larger model, while average steady-state tafamidis concentration did not meet the selection criteria.

This is the first evidence drawn from a randomized, placebo-controlled trial dataset linking early TTR increases to mortality in tafamidis-treated patients. Previous real-world studies have produced mixed results: some found no significant association between TTR changes and cardiovascular events or survival, while a single-center cohort did observe that rising TTR concentration was associated with reduced mortality. Comparable findings have also emerged for acoramidis, another TTR kinetic stabilizer, in the phase 3 ATTRibute-CM study, where every 5 mg/dL increase in TTR at month 1 was associated with a 31.6% reduction in the odds of death and a 26.6% relative reduction in the hazard of death.

The researchers caution that the mechanisms behind treatment-related TTR increases remain incompletely understood. Stabilization of TTR could theoretically raise blood concentrations through three routes: improving secretion of the protein from liver cells, prolonging its lifetime in the circulation, or preventing its aggregation and deposition as amyloid. Only the last is thought to be directly tied to treatment efficacy, and the relative contribution of each mechanism is uncertain. TTR levels are also influenced by inflammation and nutritional state, which may confound interpretation in individual patients.

For these reasons, the authors conclude that serum TTR cannot be regarded as a reliable biomarker of therapeutic response, and that its incremental value beyond established prognostic measures such as cardiac biomarkers and functional capacity assessments remains unclear. As a post hoc analysis restricted to patients who survived the first month of treatment, the study demonstrates associations rather than established causal effects, and the authors call for future research to clarify the biology of TTR concentration changes and determine whether they add prognostic information beyond existing tools.

Subject of Research: Association between early TTR concentration changes on tafamidis and all-cause mortality in transthyretin amyloid cardiomyopathy

Article Title: Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACT

Article References: Maurer, M. S., Elliott, P., Kelly, J. W., Hanna, M., Powers, E. T., Riley, S., Wang, R., & Garcia-Pavia, P. (2026). Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACT. Cardiology and Therapy, 15(S1), 1-18. https://doi.org/10.1007/s40119-026-00468-2

Image Credits: AI Generated

DOI: 10.1007/s40119-026-00468-2

Keywords: tafamidis, transthyretin amyloid cardiomyopathy, ATTR-ACT, TTR concentration, all-cause mortality, kinetic stabilizer, post hoc analysis, phase 3 trial, biomarker, cardiomyopathy, Impact, Transthyretin